### Albendazole

**Indication**
- Cysticercosis of central nervous system

**INN**
- Albendazole

**Medicine type**
- Chemical agent

**List type**
- Complementary

**Formulations**
- Oral > Solid > tablet: 400 mg (chewable, scored); 200 mg (chewable) (EMLc)

**EML status history**
- First added in 2021 (TRS 1035)
- Changed in 2023 (TRS 1049)

**Sex**
- All

**Age**
- Also recommended for children

**Therapeutic alternatives**
- The recommendation is for this specific medicine

**Patent information**
- Patents have expired in most jurisdictions
  
  Read more about patents.

**Wikipedia**
- Albendazole

**DrugBank**
- Albendazole

---

**Summary of evidence and Expert Committee recommendations**

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the listings for albendazole 400 mg chewable tablets on the EML and EMLc be amended to specify that they be scored. Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the addition of a new strength formulation (200 mg chewable tablets) to the EMLc for treatment of diseases caused by taeniid cestode cysts.